Table 6.
Treatment-related clinical adverse events in XT and T arms
| Adverse Event | XT (n=61) (%) |
T (n=70) (%) |
P-value* |
|---|---|---|---|
| 3/4 grade adverse events | 17 (28) | 12 (17) | 0.140 |
| 3/4 grade leukopenia | 12 (20) | 10 (14) | 0.411 |
| 3/4 grade nausea, vomiting, and diarrhea | 4 (7) | 1 (1) | 0.126 |
| 3/4 grade mucositis | 1 (3) | 1 (1) | 0.922 |
| HFS | 10 (16) | 0 (0) | 0.000 |
| Alopecia | 61 (100) | 69 (99) | 1.000 |
Note:
*
P-value by chi-square test or Fisher’s exact test when the cell expectation was less than six.
Abbreviations: HFS, hand-foot syndrome; XT, capecitabine/docetaxel; T, docetaxel.